HC Wainwright & Co. Maintains Buy on Akebia Therapeutics, Raises Price Target to $6
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Ed Arce maintains a Buy rating on Akebia Therapeutics (NASDAQ:AKBA) and raises the price target from $5 to $6.
March 28, 2024 | 4:20 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Akebia Therapeutics' Buy rating is maintained by HC Wainwright & Co., with the price target increased from $5 to $6.
The maintenance of a Buy rating combined with an increased price target typically signals a positive outlook on the stock by the analyst, suggesting an expectation of upward price movement in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100